Finance

Beta
Lists
TARS:NASDAQ
Tarsus Pharmaceuticals Inc
$61.95
-1.05%
(-0.66) 1D
$61.95
0.00% (0.00)
After hours
Closed: Jun 12, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TARS...
Open
$62.70
High
$63.61
Low
$61.71
Mkt. cap
2.67B
Avg. vol.
734.02K
Volume
267.32K
52-wk high
$85.25
52-wk low
$38.51
EPS
-$1.13
Beta
0.49
Shares outstanding
43.02M
No. of employees
370
Open
$62.70
High
$63.61
Low
$61.71
Mkt. cap
2.67B
Avg. vol.
734.02K
Volume
267.32K
52-wk high
$85.25
52-wk low
$38.51
EPS
-$1.13
Beta
0.49
Shares outstanding
43.02M
No. of employees
370
Analyst outlook
Analyst Ratings
Based on 8 analysts giving stock ratings to TARS in the past 3 months
Strong Buy
Buy
8
Hold
0
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for TARS in the last 3 months.
Highest
Current $61.95
$100.00 (+61.42%)
Average
$95.17 (+53.62%)
Lowest
$88.00 (+42.05%)
News stories
From sources across the web
About Tarsus Pharmaceuticals Inc
CEO-
Employees370
Founded2016
HeadquartersIrvine, California, United States
SectorPharmaceutical industry
Websitetarsusrx.com
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.16 / -$0.45
+64.25%beat
Revenue / Est. (USD)
162.05M / 147.79M
+9.65%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
102.66M
118.70M
151.67M
162.05M
Cost of goods sold
21.83M
24.59M
28.96M
31.75M
Cost of revenue
21.83M
24.59M
28.96M
31.75M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
103.01M
108.63M
130.68M
136.43M
Operating expense
103.01M
108.63M
130.68M
136.43M
Total operating expenses
124.84M
133.23M
159.64M
168.18M
Operating income
-22.18M
-14.53M
-7.98M
-6.12M
Other non operating income
-145.00K
98.00K
4.48M
-936.00K
EBT including unusual items
-20.34M
-12.58M
-6.31M
-4.62M
EBT excluding unusual items
-20.34M
-12.58M
-1.76M
-5.46M
Income tax expense
-
-
2.06M
2.35M
Effective tax rate
-
-
-32.61%
-50.96%
Other operating expenses
-
-
-
-
Net income
-20.34M
-12.58M
-8.37M
-6.97M
Net profit margin
-19.81%
-10.60%
-5.52%
-4.30%
Earnings per share
-0.48
-0.30
-0.20
-0.16
Interest and investment income
4.23M
4.11M
3.95M
3.72M
Interest expense
-2.24M
-2.27M
-2.21M
-2.13M
Net interest expenses
1.99M
1.85M
1.74M
1.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.73M
-14.07M
-7.53M
-5.68M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer